Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study.

doi:10.1158/2767-9764.CRC-26-0184

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study.

Cancer research communications - 1 Jul 2026

Aggarwal Rahul, Italiano Antoine, Domchek Susan M, Goodman Oscar, Postel-Vinay Sophie, Garcia-Donas Jesus, Dorff Tanya, Reichert Zachery R, Vinceneux Armelle, Shore Neal, Marshall Catherine H, Armenia Joshua, Parr Graeme, Kmieciak Aleksandra, Lukashchuk Natalia, Murina Olga, Slade Daniel, Shah Neel, Loembé Bienvenu, Dean Emma, Sanai Elhan, Abida Wassim

Abstract excerpt

PURPOSE: Ceralasertib is an oral ataxia telangiectasia and Rad3-related (ATR) inhibitor with preclinical activity in ataxia-telangiectasia mutated (ATM)-altered cancers. The phase IIa PLANETTE study evaluated ceralasertib in previously treated advanced solid tumors (cohort A) or metastatic castration-resistant prostate cancer (cohort B) with ATM alterations (ATM mutations and/or ATM protein deficiency). PATIENTS...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ataxia Telangiectasia Mutated Proteins

Share to Indoles

Share to Morpholines

Share to Progression-Free Survival

Share to Prostatic Neoplasms, Castration-Resistant

Share to Pyrimidines

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 42219553
DOI: 10.1158/2767-9764.CRC-26-0184
PMCID: PMC13324620

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study.PMID 42219553Read ↗

512O Interim results from a phase II study of the ATR inhibitor ceralasertib in ARID1A-deficient and ARID1A-intact advanced solid tumor malignanciesSemantic proximity Read ↗

Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)Semantic proximity Read ↗

Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)Semantic proximity Read ↗

Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial resultsSemantic proximity Read ↗

Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response DefectsSemantic proximity Read ↗

Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.Semantic proximity Read ↗

ATM Mutations in Cancer: Therapeutic Implications.Semantic proximity Read ↗

34O ATR inhibitor alone (ceralasertib) or in combination with olaparib in gynaecological cancers with ARID1A loss or no loss: Results from the ENGOT/GYN1/NCRI ATARI trialSemantic proximity Read ↗

First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid TumorsSemantic proximity Read ↗

Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I.Semantic proximity Read ↗

A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer.Semantic proximity Read ↗

US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.